Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global inflammatory bowel disease treatment market size was valued at USD 20.33 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 3.6% from 2023 to 2030. The rising prevalence of ulcerative colitis and Crohn’s disease across the globe is anticipated to drive market growth in the forecast period. In addition, the presence of robust pipeline candidates such as AbbVie’s Skyrizi (risankizumab) & Rinvoq (upadacitinib), Lilly’s mirikizumab, Takeda’s subcutaneous formulation of Entyvio (vedolizumab), and a surge in adoption of biological drugs for the treatment of IBD is likely to contribute to the market expansion. There has been a surge in government initiatives to improve healthcare services for patients living with IBD, as these patients are more susceptible to acquiring infections owing to immunosuppressive therapies.

The rising prevalence of ulcerative colitis and Crohn’s disease is anticipated to fuel the growth of the inflammatory bowel disease treatment market. According to the Crohn’s & Colitis Foundation of America, more than 1.6 million Americans have ulcerative colitis & Crohn’s disease and an estimated 70,000 new cases of IBD are diagnosed in the U.S. every year. In addition, according to the RAH Research Fund, there are more than 80,000 individuals living with IBD in Australia.

The presence of a strong product pipeline and expected launches during the forecast period are projected to drive market growth. For instance, AbbVie’s ABBV-154 is an anti-TNF GRM ADC currently in phase II of clinical trials and is expected to launch in the coming years. Similarly, Lilly’s Mirikizumab is a large molecule potentially being investigated for IBD treatment and is expected to be commercialized by 2023. Current therapies focus on reducing inflammation, risks of complications, and long-term remission. Moreover, hospitals & healthcare institutes are working closely with pharmaceutical companies for conducting clinical trials and ensuring the safety of patients. Such initiatives are expected to increase the research activities to develop a novel treatment for IBD.

Moreover, technological advancements form a key trend in gaining traction for the IBD treatment market. For example, the leading participants in the IBD treatment market are emphasizing on adoption of advanced technologies like AI for drug discovery and offering new treatments for Crohn’s disease and ulcerative colitis. To attain technological innovations, leading companies and tech innovators are collaborating to leverage each other’s technologies and competencies to innovate novel regimens and strengthen their market position. For instance, in May 2021, CytoReason, an Israel-based tech company, announced a partnership with Ferring Pharmaceuticals to accelerate the drug development process and innovate novel therapeutics for IBD using AI technology.

Furthermore, the increase in the adoption of strategies such as product launches, development, expansions, and collaborations is projected to support market expansion. For instance, in March 2022, AbbVie, Inc. received U.S. FDA approval for its RINVOQ, a Janus kinase inhibitor, for the treatment of ulcerative colitis. In addition, in May 2020, AbbVie, Inc. announced the completion of its acquisition of Allergan, which is expected to expand its product portfolio for IBD treatment. Moreover, the increasing adoption of novel products and large molecules is anticipated to support market growth over the forecast period.

Type Insights

The Crohn’s disease segment held the largest share of 60.9% of the market in 2022 and is anticipated to maintain its position over the forecast period. Factors such as the increasing prevalence of the condition, the high cost associated with Crohn’s disease treatment, and the surge in prescription rates of biologics are fueling the segment expansion. Moreover, the presence of strong pipeline candidates expected to launch in the coming years is expected to facilitate segment growth. For instance, in November 2022, the European Commission granted approval for Skyrizi IV for the treatment of moderate to severe Crohn’s disease.

However, the ulcerative colitis segment is likely to expand at a lucrative growth rate during the projected period, owing to increasing approval of biologics for the treatment of ulcerative colitis and a high patient base. Patients with ulcerative colitis accounted for 54% of the diagnosed IBD patients in Europe and the U.S. In addition, the adoption of biologic therapies to manage ulcerative colitis disease is likely to increase at a lucrative rate in the projected period. Furthermore, companies are collaborating to address the increased demand for therapeutic drugs for ulcerative colitis. For instance, in July 2022, Athos Therapeutics announced plans for research collaboration with Lahey Hospital and Medical Center in Burlington, Massachusetts for the development of precision medicine in IBD and ulcerative colitis.

Drug Class Insights

The TNF inhibitors segment held the largest market share of the inflammatory bowel disease treatment market in 2022. The large segment share can be attributed to the surge in the prescription rate of TNF inhibitors for the treatment of IBD and rising consumer awareness about TNF inhibitors. Some of the key TNF inhibitors are Humira, Remicade, Simponi, Cimzia, and other biosimilars used to treat inflammatory diseases. However, the loss of patent protection for TNF inhibitors is anticipated to hamper the market growth in the coming years.

Moreover, companies are focusing on label expansion of existing products to strengthen their presence in the market. For instance, in February 2021, AbbVie, Inc. received U.S. FDA approval for Humira to treat moderate-to-severe ulcerative colitis in patients aged 5 & above. Similarly, Johnson & Johnson Services, Inc. is currently evaluating the safety and efficacy of Simponi in pediatric patients with active ulcerative colitis.

JAK inhibitors segment is expected to expand at the fastest growth rate in the forecast period. The growth of the segment can be attributed to the increasing approval of novel JAK inhibitors and the presence of strong pipeline drugs, which are expected to be commercialized in the coming years. For instance, in March 2022, the U.S. FDA approved Rinvoq (upadacitinib) for the treatment of adult patients having active ulcerative colitis. Similarly, in November 2021, the European Commission approved an additional indication for Jyseleca (filgotinib) for the treatment of active ulcerative colitis in adult patients.

Route Of Administration Insights

In 2022, the injectable segment held the largest market share of 77.5% owing to the high adoption rate of biologics and biosimilar preparations, coupled with higher prices, rapid onset of action of injectable drugs, and higher bioavailability of injectable drugs. In addition, the robust availability of injectable therapeutics for the management of IBD has increased the segment share. For instance, the higher prescription rate of injectable formulations such as Humira (adalimumab), Remicade (infliximab), Stelara (ustekinumab), Cimzia (certolizumab), Entyvio (vedolizumab), and others is supporting the large market share of injectable drugs.

The oral segment is projected to expand at a lucrative rate throughout the forecast period, owing to rising demand for novel oral formulations, coupled with growing efforts from drug makers to develop oral preparations for inflammatory bowel disease treatment. Moreover, the rising regulatory approvals of JAK inhibitors and increasing research activities in oral drug development such as S1P modulators and JAK inhibitors are projected to support segment expansion in the coming years.

Distribution Channel Insights

The hospital pharmacies segment captured a 46.1% revenue share of the IBD treatment market in 2022. Factors such as high hospitalization rates, increasing severity of IBD, and a surge in the geriatric population are expected to drive the segment growth. Moreover, betterment in reimbursement policies in developed and developing economies, which cover high-priced IBD therapeutic products, is expected to fuel the segment growth. On the other hand, the retail pharmacy segment held the second-largest share in the inflammatory bowel disease treatment market.

The online pharmacies segment is likely to be the fastest-growing segment during the forecast period. The increasing trend of online pharmacies, rising internet penetration, and various discounts offered by online pharmacy players are some of the key factors contributing to the segment expansion. Moreover, increased adoption of telemedicine during & after the COVID-19 pandemic is further anticipated to boost the segment growth. In addition, the availability of self-administered prefilled syringes & prefilled pens is increasing the shift of consumers toward online pharmacies.

Regional Insights

North America led the global inflammatory bowel disease treatment market due to the presence of many strong market players, coupled with various strategic initiatives undertaken by them in the region. Moreover, the increasing prescription of novel drugs, high treatment rates, and better reimbursement policies in the region are facilitating regional expansion. In addition, ongoing research activities to develop novel therapeutics and supportive government policies are anticipated to drive the region’s growth. For instance, Crohn’s & Colitis Foundation is one of the key organizations that support various clinical and translational research to find cures for colitis and Crohn’s disease.

Asia Pacific is projected to witness the fastest growth rate over the forecast period. The increasing geriatric population, coupled with the high risk of developing inflammatory diseases, increasing prevalence of inflammatory bowel diseases, and improvement in healthcare policies in the region are some of the primary factors fueling market growth in the coming years. In addition, the increasing adoption of biosimilar & biologics and rising investments by leading participants in the region are projected to propel the market growth in the near future.

Key Companies & Market Share Insights

Key market players are adopting strategies such as new product development, mergers & acquisitions, and partnerships to increase their market share. Market players such as AbbVie Inc., Takeda Pharmaceutical Company Limited, Biogen, and others are actively involved in the development of novel treatments for inflammatory bowel disease. For instance, in March 2020, Celltrion Healthcare launched Remsima SC in Europe for the treatment of UC and Crohn’s disease. Moreover, pipeline drugs such as brazikumab, mirikizumab, etrolizumab, etrasimod, and others are expected to increase the market growth. Some prominent players in the global inflammatory bowel disease treatment market include:

• AbbVie Inc

• Takeda Pharmaceutical Company Limited

• Pfizer Inc

• Biogen

• Novartis AG

• Lilly

• UCB S.A.

• CELLTRION INC.

• Merck & Co., Inc.

• Johnson & Johnson Services, Inc

Inflammatory Bowel Disease Treatment Market Report Scope

 
Global Inflammatory Bowel Disease Treatment Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global inflammatory bowel disease treatment market report based on type, drug class, route of administration, distribution channel, and region.

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Crohn's Disease

  • Ulcerative Colitis

• Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

  • Aminosalicylates

  • Corticosteroids

  • TNF inhibitors

  • IL inhibitors

  • Anti-integrin

  • JAK inhibitors

  • Others

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Oral

  • Injectable

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Singapore

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait